



Privileged & Confidential

Via E-Mail (AGO.highcostprescriptiondrugs@vermont.gov)

June 30, 2023

Susanne R. Young
Attorney General
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

Re: Notice of New Prescription Drug to Market

Dear Ms. Young:

Pursuant to 18 VT. STAT. ANN. § 4637(b), this letter shall serve as notice that BioMarin Pharmaceutical Inc. ("BioMarin") released ROCTAVIAN™ (NDC 68135-0927-48), "a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program" on June 29, 2023.

18 VT. STAT. ANN. § 4637 does not currently define "release of the drug in the commercial market." Further, BioMarin is not aware of any guidance issued by the Vermont Attorney General's Office or any Vermont regulation that defines "release of the drug in the commercial market" for the purpose of 18 VT. STAT. ANN. § 4637. BioMarin interprets "release of the drug in the commercial market" to mean the date upon which BioMarin submits ROCTAVIAN's wholesale acquisition cost to a pricing compendia.

Please contact Erica Ahanotu, Corporate Counsel, at statepricetransparency@bmrn.com if you have any questions.

Sincerely,

DS
EA

DocuSigned by:

86553D47CEF64BD...

Heather Ollison

GVP, Commercial Operations North America